Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 17/20 | 0.49 |
| ▸ | ITGB2 | P05107 | 3/20 | 0.41 |
| ▸ | ICAM1 | P05362 | 3/20 | 0.41 |
| ▸ | ITGAL | P20701 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16025655 | 0.91 | LRRK2 (0.50) | LRRK2 | |
| SCHEMBL19672003 | 0.90 | LRRK2 (0.47) | LRRK2 | |
| SCHEMBL17430380 | 0.90 | LRRK2 (0.61) | LRRK2 | |
| SCHEMBL16025886 | 0.88 | LRRK2 (0.61) | LRRK2 | |
| SCHEMBL17430370 | 0.86 | LRRK2 (0.53) | LRRK2 | |
| SCHEMBL16025701 | 0.86 | LRRK2 (0.48) | LRRK2 | |
| SCHEMBL17430356 | 0.86 | ADORA2A (0.38) | LRRK2 | |
| SCHEMBL16025582 | 0.85 | LRRK2 (0.49) | LRRK2 | |
| SCHEMBL16025959 | 0.85 | LRRK2 (0.63) | LRRK2 | |
| SCHEMBL16025597 | 0.85 | LRRK2 (0.47) | LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2964221-B1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | MERCK SHARP & DOHME (US) | 2017-12-06 | — | — | EP | disclosed |
| US-9440952-B2 | Compounds inhibiting leucine-rich repeat kinase enzyme activity | MERCK SHARP & DOHME CORP. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9440952-B2 | Compounds inhibiting leucine-rich repeat kinase enzyme activity | MERCK SHARP & DOHME CORP. (US) | 2016-09-13 | — | — | US | disclosed |
| US-20160009682-A1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | MERCK SHARP & DOHME LLC | 2016-01-14 | — | — | US | disclosed |
| US-20160009682-A1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | MERCK SHARP & DOHME LLC | 2016-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009682-A1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | LRRK2, LRRC47, LIMK2 | LRRK2 1/4885ITGB2 3554/4885ICAM1 2400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.